Osteoarthritis of the knee

Reimbursement: £2,010

About This clinical research study

MAC Clinical Research are currently conducting a clinical trial to test a potential new treatment for moderate to severe osteoarthritis (OA) of the knee. OA causes joints to become painful and stiff and is the most common type of arthritis the hands, hip, and knee being the most prevalent joints affected by osteoarthritis.

Living with osteoarthritis of the knee, particularly when it is moderate or severe OA knee, can be a real struggle. OA knee symptoms can include limited movement, constant pain when walking and in the worst cases osteoarthritis surgery may be required. Often those with knee osteoarthritis will develop bilateral knee osteoarthritis (in both knees) but often have one knee with more prevalent symptoms.

Standard treatment for osteoarthritis includes painkillers (such as NSAID and paracetamol) for pain relief, regular exercise, and weight loss. With severe or moderate arthritis in knee, OA knee treatments may include knee injections for osteoarthritis (corticosteroid injections) and surgery. There is, therefore, a real need to find new treatments for knee osteoarthritis.

The purpose of this clinical trial is to assess the safety, tolerability, and pharmacokinetics (what the body does to a medication) of Mavatrep, the investigational treatment versus placebo. The investigational medicine works by blocking a protein (known as the “capsaicin receptor”) found in the body that is believed to cause some of the pain associated with osteoarthritis. Capsaicin for osteoarthritis pain is often used as a topical cream. However, Mavatrep, derived from capsaicin (the active ingredient found in chilli peppers) is an oral capsule.

Reimbursement: £2,010

Clinics

Merseyside

Therapy Area

Osteoarthritis

Gender and Age

Males and Females aged 25 - 79

A full description of the clinical trial will be given before you decide to take part, both over the phone and during an appointment at a MAC clinic. This will include you receiving the full patient information sheet (PIS).

Eligible participants have a 75% (3 in 4) chance of receiving the Mavatrep, and a 25% (1 in 4) chance of placebo.

The trial will last approximately 10 weeks and includes up to 12 visits at our clinic in Merseyside. Visits will include some residential stays, as well as outpatient visits, and could include an X-ray visit.

Reimbursement: £2,010

Key Inclusion Criteria

Key Exclusion Criteria

Other eligibility criteria will apply. Please contact MAC for more information.

Eligible participants will receive a comprehensive health screen and study participation will be in collaboration with the participant’s treating physician.

If you would like more information, please fill in the form below and we will be in touch…

Alternatively, please call our recruitment team on freephone 0800 633 5507.

  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
    (You can enter any supporting information here)
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
  • This field is hidden when viewing the form
Data Privacy Statement

Know someone who may be interested in taking part? Share this page here:

Facebook
Twitter
WhatsApp
Email